- Home
- PSF vs ITOS Comparison
PSF vs ITOS Comparison
Compare PSF & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- ITOS
- Stock Information
- Founded
- PSF 2010
- ITOS 2011
- Country
- PSF United States
- ITOS United States
- Employees
- PSF N/A
- ITOS N/A
- Industry
- PSF Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSF Finance
- ITOS Health Care
- Exchange
- PSF Nasdaq
- ITOS Nasdaq
- Market Cap
- PSF 244.3M
- ITOS 270.7M
- IPO Year
- PSF N/A
- ITOS 2020
- Fundamental
- Price
- PSF $19.98
- ITOS $5.63
- Analyst Decision
- PSF
- ITOS Strong Buy
- Analyst Count
- PSF 0
- ITOS 3
- Target Price
- PSF N/A
- ITOS $26.00
- AVG Volume (30 Days)
- PSF 25.0K
- ITOS 371.7K
- Earning Date
- PSF 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- PSF 7.69%
- ITOS N/A
- EPS Growth
- PSF N/A
- ITOS N/A
- EPS
- PSF N/A
- ITOS N/A
- Revenue
- PSF N/A
- ITOS $35,000,000.00
- Revenue This Year
- PSF N/A
- ITOS N/A
- Revenue Next Year
- PSF N/A
- ITOS $121.70
- P/E Ratio
- PSF N/A
- ITOS N/A
- Revenue Growth
- PSF N/A
- ITOS 177.89
- 52 Week Low
- PSF $16.00
- ITOS $5.62
- 52 Week High
- PSF $20.19
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- PSF 44.87
- ITOS 26.01
- Support Level
- PSF $19.88
- ITOS $6.32
- Resistance Level
- PSF $20.28
- ITOS $6.76
- Average True Range (ATR)
- PSF 0.23
- ITOS 0.32
- MACD
- PSF 0.00
- ITOS -0.12
- Stochastic Oscillator
- PSF 51.59
- ITOS 0.49
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.